NYSE:PRGOPharmaceuticals
Perrigo (PRGO): Discounted Valuation Challenges Bearish Turnaround Narratives Despite Ongoing Losses
Perrigo (PRGO) remained unprofitable, with annual losses accelerating by 15.2% per year over the past five years. Despite the ongoing red ink, the company is forecast to turn profitable within three years, fueled by projected annual earnings growth of 6.54%. With shares trading at $15.10, well below a fair value estimate of $95.72 and sporting a price-to-sales ratio markedly lower than both industry and peer averages, many investors are eyeing PRGO as a turnaround value opportunity. However,...